The Bond RTU Antibodies range has been expanded with the Phase 8 release, which includes the antibodies Bcl-2 and Mismatch Repair Protein.
Bcl-2 is a member of a family of proteins involved in apoptosis. It is suitable for the differentiation of follicular lymphomas from reactive lymph nodes.
Mismatch Repair Protein, also known as MSH2, is one of a family of proteins indicative of micro satellite instability. MSH2 has been used for the diagnosis of hereditary non-polyposis colorectal cancer (HNPCC).
Other antibodies added to the range are Luteinizing Hormone, Neurofilament 200 kD, Muramidase (Lysozyme) and Myeloperoxidase.
The Bond RTU range helps to standardise IHC testing and minimise manual tasks. Each antibody is optimised for use on the fully automated Bond IHC and ISH system.
There is no need to mix, dilute or titrate a Bond RTU antibody, so there is less opportunity for process variation and fewer non-productive tasks. Users simply place a registered container onto the Bond processing module along with the Bond Polymer Refine Detection system.
Once an antibody is selected, Bond automatically sets the ideal protocol and pre-treatment options. The system can then be started immediately, or a delayed start can be selected.
Phone: 1800 625 286
The FSD Fluor series is a panel of fluorescent dyes with good fluorescence intensity and a high...
BioClean products are part of Ansell Limited's Life Sciences Solutions portfolio, offering a...
Larodan develops a comprehensive range of research-grade lipids for use as analytical standards...